Table 1

Baseline characteristics and clinical outcome of the matched patients 

Total
(n=132)
With stent
(n=66)
Without stent
(n=66)
P value
Age, median(IQR), years67 (56.0–75.0)66 (55.0–76.0)67 (56.0–75.0)0.890
Male, n (%)74 (56.1)36 (54.5)38 (57.6)0.726
Hypertension, n (%)87 (65.9)47 (71.2)40 (60.6)0.199
Diabetes mellitus, n (%)24 (18.2)15 (22.7)9 (13.6)0.176
Dyslipidemia, n (%)11 (8.3)5 (7.6)6 (9.1)0.753
Coronary artery disease, n (%)30 (22.7)13 (19.7)17 (25.8)0.406
History of stroke or TIA, n (%)21 (15.9)12 (18.2)9 (13.6)0.475
Initial NIHSS, median (IQR)17 (12.0–21.0)16 (12.0–21.0)18 (13.0–21.0)0.538
ASPECTS, median (IQR)9 (8.0–10.0)9 (8.0–10.0)9 (8.0–10.0)0.879
Admission glucose, median (IQR)7.1 (5.9–9.2)7.4 (6.2–9.3)6.9 (5.8–9.2)0.571
Intravenous thrombolysis, n (%)42 (31.8)20 (30.3)22 (33.3)0.709
ASITN/SIR < 2, median (IQR)69 (52.3)32 (48.5)37 (56.1)0.384
Onset to puncture time (min), mean±SD284±88.6280±86.7289±90.90.540
Procedure time (min), median (IQR)142 (100.0–186.0)145 (102.0–192.0)133 (96.0–182.0)0.431
Passes of stentriever, median (IQR)3 (2.0–4.0)3 (1.0–4.0)3 (2.0–4.0)0.142
Balloon angioplasty, n (%)38 (28.8)18 (27.3)20 (30.3)0.701
Intra–arterial Tirofiban, n (%)34 (25.8)18 (27.3)16 (24.2)0.691
Intra–arterial rtPA or urokinase, n (%)12 (9.1)7 (10.6)5 (7.6)0.545
Successful reperfusion, n (%)57 (43.2)57 (86.4)0 (0.0)0.000
Symptomatic ICH, n (%)23 (17.4)9 (13.6)14 (21.2)0.251
mRS (0–2), n (%)37 (28.0)24 (36.4)13 (19.7)0.033
Mortality, n (%)50 (37.9)21 (31.9)29 (43.9)0.151
  • ASITN/SIR, American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology; ASPECTS, Alberta Stroke Program Early CT Score; ICH, intracerebral hemorrhage; mRS, modified Rankin scale.; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack